| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: Departments of 1 Nuclear Medicine, 2 Radiology, 3 Internal Medicine III, and 4 Pathology, and 5 Institute for Medical Statistics and Epidemiology, Technische Universität München, Munich, Germany
Requests for reprints: Ken Herrmann, Department of Nuclear Medicine, Technische Universität München, Ismaningerstrasse 22, D-81675 Munich, Germany. Phone: 49-89-4140-2962; Fax: 49-89-4140-4950; E-mail: ken.herrmann{at}web.de.
Purpose: To evaluate 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography (FLT-PET) for early monitoring response of high-grade non-Hodgkin's lymphoma to treatment with cyclophosphamide-adriamycin-vincristine-prednisone chemotherapy with or without rituximab immunotherapy (R-CHOP/CHOP).
Experimental Design: Twenty-two patients with histologically proven high-grade non-Hodgkin's lymphoma scheduled to undergo first line treatment with R-CHOP/CHOP were included. All patients received baseline imaging before therapy with FLT-PET. For noninvasive assessment of treatment response, FLT-PET was repeated at following time points: group 1 (n = 6), 1 and 6 weeks after R-CHOP/CHOP; group 2 (n = 16), 2 days after rituximab and 2 days after CHOP application. Emission images were acquired 45 min after injection of 300 to 370 MBq of FLT. FLT uptake was quantified by region-of-interest technique on a lesion basis. Maximum standardized uptake values (SUV) for FLT were calculated using circular region of interest (diameter, 1.5 cm).
Results: In all patients, morphologically proven lesions showed initially high FLT uptake (mean SUV, 8.1 ± 3.9). In group 1, mean FLT SUV decreased 7 days after R-CHOP/CHOP by 77% (P < 0.001), the reduction in FLT SUV from baseline was 85% after 40 days (P = 0.003). In group 2, FLT uptake in patients without dexamethasone pretreatment revealed no significant reduction after rituximab (P = 0.3) but significantly decreased 2 days after CHOP to 32% compared with the baseline value (P = 0.004).
Conclusions: Administration of R-CHOP/CHOP is associated with an early decrease in lymphoma FLT uptake. Interestingly, there was no reduction of FLT uptake after rituximab alone, indicating no early antiproliferative effect of immunotherapy. FLT-PET seems to be promising for early evaluation of drug effects in lymphoma.
This article has been cited by other articles:
|
|
 |
|
  L. Brepoels, S. Stroobants, G. Verhoef, T. De Groot, L. Mortelmans, and C. De Wolf-Peeters 18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model J. Nucl. Med., July 1, 2009; 50(7): 1102 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Vail, D. H. Thamm, H. Reiser, A. S. Ray, G. H.I. Wolfgang, W. J. Watkins, D. Babusis, I. N. Henne, M. J. Hawkins, I. D. Kurzman, et al. Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma Clin. Cancer Res., May 15, 2009; 15(10): 3503 - 3510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schoder, M. Fury, N. Lee, and D. Kraus PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 74S - 88S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Larson Molecular Imaging In Tumor Treatment Response Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 261 - 264. [Full Text] [PDF]
|
|
|
|
|
|
B. Zhao, L. H. Schwartz, and S. M. Larson Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers J. Nucl. Med., February 1, 2009; 50(2): 239 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Sohn, Y.-J. Yang, J.-S. Ryu, S. J. Oh, K. C. Im, D. H. Moon, D. H. Lee, C. Suh, J.-S. Lee, and S.-W. Kim [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung Clin. Cancer Res., November 15, 2008; 14(22): 7423 - 7429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, M. Bommer, M. E. Juweid, G. Glatting, S. Stilgenbauer, F. M. Mottaghy, M. Schulz, T. Kull, D. Bunjes, P. Moller, et al. First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine J. Nucl. Med., November 1, 2008; 49(11): 1756 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A V Martin and B Sharma Positron emission tomography and CT in the management of lymphoma Imaging, September 1, 2008; 20(3): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Herrmann, F. Eckel, S. Schmidt, K. Scheidhauer, B. J. Krause, J. Kleeff, T. Schuster, H.-J. Wester, H. Friess, R. M. Schmid, et al. In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors J. Nucl. Med., September 1, 2008; 49(9): 1437 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Reiser, J. Wang, L. Chong, W. J. Watkins, A. S. Ray, R. Shibata, G. Birkus, T. Cihlar, S. Wu, B. Li, et al. GS-9219--A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non-Hodgkin's Lymphoma Clin. Cancer Res., May 1, 2008; 14(9): 2824 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. Schuster, H.-J. Wester, J. R. Siewert, et al. Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis J. Nucl. Med., December 1, 2007; 48(12): 1945 - 1950. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
